PharmaResearch Co Ltd
KOSDAQ:214450
PharmaResearch Co Ltd
Gross Profit
PharmaResearch Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Gross Profit
â‚©225B
|
CAGR 3-Years
31%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Celltrion Inc
KRX:068270
|
Gross Profit
â‚©1.3T
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
||
SK Bioscience Co Ltd
KRX:302440
|
Gross Profit
â‚©142.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
||
Green Cross Corp
KRX:006280
|
Gross Profit
â‚©463.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
||
H
|
Hugel Inc
KOSDAQ:145020
|
Gross Profit
â‚©278.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
KOSDAQ:196170
|
Gross Profit
â‚©32.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
PharmaResearch Co Ltd
Glance View
In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.
See Also
What is PharmaResearch Co Ltd's Gross Profit?
Gross Profit
225B
KRW
Based on the financial report for Sep 30, 2024, PharmaResearch Co Ltd's Gross Profit amounts to 225B KRW.
What is PharmaResearch Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
38%
Over the last year, the Gross Profit growth was 24%. The average annual Gross Profit growth rates for PharmaResearch Co Ltd have been 31% over the past three years , 38% over the past five years .